Target intelligence / Profile preview

Ras homolog family member C (RhoC)

Target
RhoC
Molecular classification
Small GTPase, Enzyme, Signal transduction protein, Rho family GTPase, Cytoskeletal regulator
01

Overview

Ras homolog family member C (RhoC) is a small GTPase enzyme (~21 kDa), and a member of the Rho family of GTP-binding proteins that regulate actin cytoskeleton organization, cell motility, and cell shape[1][6]. RhoC cycles between active GTP-bound and inactive GDP-bound states, functioning as a molecular switch in signal transduction[1][3][4]. It is mainly localized to the cytoplasm and plasma membrane, where it regulates the assembly of focal adhesions, actin stress fibers, and cell contractility[6]. RhoC is essential for cell directional migration and speed, modulating cell motility during normal processes and in cancer metastasis[1]. Overexpression or aberrant activation of RhoC has been implicated in various cancers, driving tumor cell invasion, metastasis, and angiogenesis[1][3][2]. It participates in cancer-related signal pathways suchs as MAPK, PI3K/AKT, and Notch, as well as cytoskeletal effectors (IQGAP1, ROCK-1, MMP9, FMNL3)[1]. RhoC is considered a promising cancer biomarker and therapeutic target, with RNA interference and vaccine-based therapies currently under investigation[1].

Other names
H9ARH9ARHCRHOH9rho-related GTP-binding protein RhoC
02

Mechanism of action

Inhibition of GTPase signaling, suppression of cell proliferation, inhibition of metastasis, and inhibition of cytoskeletal rearrangement.

03

Biological functions

Signal transductionCytoskeletal organizationCell shapeCell motilityCell proliferationCell cycle regulationAngiogenesis
04

Disease associations

CancerCancer metastasisTumor progressionInflammatory breast cancerOther solid tumors (lung, liver, ovarian, pancreatic, melanoma, prostate, cervical)
05

Safety considerations

Target specificity (potential redundancy with other Rho GTPases)critical roles in cell motility and cytoskeleton (risk of interfering with normal cell migration)possible off-target immunological effects from immunotherapies
06

Interacting drugs

Small interfering RNA (siRNA) therapies

2 more in the full profile.

07

Biomarkers

RhoC expression for metastatic potentialdisease progression in cancer

Beyond the preview

Go deeper on Ras homolog family member C (RhoC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ras homolog family member C (RhoC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call